Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Magainin Pharm (MAGN) -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (186)	6/21/1999 2:20:00 AM
From: BulbaMan	Read Replies (1) \| Respond to of 233

Mike: I guess I didn't make my point clear. It's not that I expect Pfizer shareholders to buy MAGN; rather, I think the FDA should be more inclined to approve MAGN's Locilex as an anti-infective now that there's greater concern about the safety of Trovan. At $1.75, MAGN's stock price essentially reflects zero chance of Locilex's approval, so a surprise from the FDA could move the stock much higher. And it seems that Trovan's troubles have lifted Locilex's chances for approval well above zero (although they're certainly not 100%). Therefore, with little downside at its current price and lots of upside, I figure MAGN's stock is a pretty decent bet.

To: Mike McFarland who wrote (186)	6/26/1999 10:50:00 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 233

Keepin' is simple... These studies support the role of pexiganan in the treatment of resistant bacteria causing diabetic foot ulcer infections. (you could launch a whole thread with this stuff) Bacteria Build Up Immunity to Antibiotics aaas.org Perhaps the overwhelming reason for antibiotic microbial resistance is the overabundance of prescribed antibiotics. No kidding. A River of Resistance biomednet.com vancomycin-resistant Enterococcus bacteria free-floating in the Rio Grande.